Shanghai's First CyberKnife(R) System Installed at Major Academic Oncology Center

Shanghai's First CyberKnife(R) System Installed at Major Academic Oncology Center

November 27, 2007

Install Marks the Fifth System in China and 121st
CyberKnife System Installation


    SUNNYVALE, Calif, Nov. 27 /Xinhua-PRNewswire/ --
Accuray Incorporated (Nasdaq: ARAY), a global leader in the
field of radiosurgery, announced today that Hua Shan
Hospital in Shanghai has installed a CyberKnife(R) Robotic
Radiosurgery System for its Pudong District facility. The
installation marks the first CyberKnife System in Shanghai
and the fifth System in China, providing greater patient
access to the benefits of robotic radiosurgery.

    "Hua Shan Hospital's reputation as a premier
provider of health care in Shanghai and the surrounding
region makes it a perfect location for the region's first
CyberKnife System," said Euan S. Thomson, Ph.D.,
president and chief executive officer of Accuray
Incorporated. "This installation is another step
toward universal access to CyberKnife radiosurgery as a
non-surgical option for cancer care." 

    The Hua Shan Hospital installation is the 121st
CyberKnife installation to date. China's previous four
CyberKnife Systems are located at Hong Kong Adventist
Hospital in Hong Kong, Shandong LuTai Tumour Hospital in
the Jinan Shandong Province, Tianjin Cancer Hospital in
Tianjin, and Ruikang Hospital in Nanning, Guangxi province.


    Hua Shan Hospital has been in partnership with Harvard
Medical International since 2001 and serves as the primary
teaching hospital of the Fudan University Medical School.
Hua Shan Hospital has created a network of facilities to
address the emerging needs of the country's people. The
network currently includes Hua Shan Hospital in Shanghai's
embassy district, Hua Shan Hospital in Pudong, and Nanchang
Zhonghuan Hospital. The hospital's facility in Pudong serves
as a center of excellence in oncology.

    About the CyberKnife(R) Robotic Radiosurgery System

    The CyberKnife Robotic Radiosurgery System is the
world's only robotic radiosurgery system designed to treat
tumors anywhere in the body non-invasively. Using continual
image guidance technology and computer controlled robotic
mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in
real-time throughout the treatment. This enables the
CyberKnife System to deliver high-dose radiation with
pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or
body stabilization frames.

    About Accuray

    Accuray Incorporated (Nasdaq: ARAY), based in
Sunnyvale, Calif., is a global leader in the field of
radiosurgery dedicated to providing an improved quality of
life and a non-surgical treatment option for those
diagnosed with cancer. Accuray develops and markets the
CyberKnife Robotic Radiosurgery System, which extends the
benefits of radiosurgery to include extracranial tumors,
including those in the spine, lung, prostate, liver and
pancreas. To date, the CyberKnife System has been used to
treat more than 40,000 patients worldwide and currently
more than 100 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more
information, please visit http://www.accuray.com. 

    Safe Harbor Statement 

    The foregoing may contain certain forward-looking
statements that involve risks and uncertainties, including
uncertainties associated with the medical device industry.
Except for the historical information contained herein, the
matters set forth in this press release regarding procedure
growth and market acceptance, clinical studies, regulatory
review and approval, and commercialization of products are
forward-looking statements within the meaning of the
"safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements speak only as of the date the statements are
made and are based on information available at the time
those statements are made and/or management's good faith
belief as of that time with respect to future events. You
should not put undue reliance on any forward-looking
statements. Important factors that could cause actual
performance and results to differ materially from the
forward-looking statements we make include: market
acceptance of products; competing products, the combination
of our products with complementary technology; and other
risks detailed from time to time under the heading
"Risk Factors" in our report on Form 10-Q for the
quarterly period ended September 29, 2007  and may be
updated from time to time by our other filings with the
Securities and Exchange Commission. The Company's actual
results of operations may differ significantly from those
contemplated by such forward-looking statements as a result
of these and other factors. We assume no obligation to
update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes
in other factors affecting forward-looking information,
except to the extent required by applicable securities
laws. 






    For more information, please contact:

     Susan Lehman
     Rockpoint Public Relations
     Tel:   [phone]
     Email: [e-mail]

     Stephanie Tomei
     Accuray Public Relations Manager
     Tel:   [phone]
     Email: [e-mail]